Table 1.
Characteristics of the 138 patients treated with pemafibrate
| Male/female | 88/50 | |
| Age (years) | 59 (21–89) | |
| Body height (m) | 163.2 (143–185) | |
| Pre-treatment body weight (kg) | 70 (42.5–109.5) | |
| Pre-treatment BMI (kg/m2) | 26.0 (18.3–40.6) | |
| Comorbidities | ||
| T2DM | 34 | 24.6% |
| Chronic hepatitis B* | 0 | 0% |
| CAD | 8 | 5.8% |
| IBD | 0 | 0% |
| Other | 24 | 17.4% |
| Biopsy-proven NASH | 6 | 4.3% |
| Pre-treatment laboratory values | ||
| TG (mg/dL) | 387.3±49.6 | |
| HDL-cholesterol (mg/dL) | 48.6±1.6 | |
| LDL-cholesterol (mg/dL) | 113.7±2.9 | |
| AST (U/L) | 42.8±2.3 | |
| ALT (U/L) | 53.8±3.6 | |
| GGT (U/L) | 96.2±9.9 | |
| HbA1c (%) | 6.5±0.1 | |
| FIB-4 index | 1.95±0.18 | |
| APRI | 0.72±0.05 | |
| eGFR | 71.8±21.8 | |
| Type IV collagen | 5.31±2.6 | |
| Autotaxin | 55.9±33.5 | |
| Concomitant medications | ||
| DPP4 antagonist | 12 | 8.7% |
| Metformin | 7 | 5.1% |
| SGLT2 inhibitor | 9 | 6.5% |
| EPA | 6 | 4.3% |
| Statin | 15 | 10.9% |
| Ezetimibe | 4 | 2.9% |
| UDCA | 12 | 8.7% |
| Duration of pemafibrate administration (weeks) | 120 (98–138) | |
APRI, aspartate aminotransferase to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; HbA1c, hemoglobin A1c; CAD, coronary artery disease; CT, computed tomography; DPP4, dipeptidyl peptidase-4; EPA, eicosapentaenoic acid; GERD, gastroesophageal reflux disease; GGT, gamma-glutamyl transpeptidase; HDL, high-density lipoprotein; IBD, inflammatory bowel disease; LDL, low-density lipoprotein; MRI, magnetic resonance imaging; SGLT2, sodium-glucose cotransporter 2; T2DM, type 2 diabetes mellitus; TG, triglyceride; UDCA, ursodeoxycholic acid; US‚ ultrasonography
*HBV DNA is controlled under detection by nucleotide analog treatment. aHypertension. Data are expressed as median (range) or mean SEM. Numbers in parentheses refer to the percentage of patients